Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Molecular basis of USP7 inhibition by selective small-molecule inhibitors.

Autor: Turnbull AP; CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, London NW1 0NH, UK., Ioannidis S; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Krajewski WW; CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, London NW1 0NH, UK., Pinto-Fernandez A; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK., Heride C; Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool L69 3BX, UK., Martin ACL; CRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, UK., Tonkin LM; CRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, UK., Townsend EC; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Buker SM; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Lancia DR; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Caravella JA; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Toms AV; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Charlton TM; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK., Lahdenranta J; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Wilker E; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Follows BC; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Evans NJ; CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, London NW1 0NH, UK., Stead L; Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool L69 3BX, UK., Alli C; CRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, UK., Zarayskiy VV; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Talbot AC; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Buckmelter AJ; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Wang M; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., McKinnon CL; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Saab F; CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, London NW1 0NH, UK., McGouran JF; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK., Century H; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK., Gersch M; Medical Research Council Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK., Pittman MS; CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, London NW1 0NH, UK., Marshall CG; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Raynham TM; CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, London NW1 0NH, UK., Simcox M; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Stewart LMD; CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, London NW1 0NH, UK., McLoughlin SB; CRUK Therapeutic Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge CB22 3AT, UK., Escobedo JA; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Bair KW; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Dinsmore CJ; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Hammonds TR; CRUK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, London NW1 0NH, UK., Kim S; FORMA Therapeutics, Arsenal Street, Watertown, Massachusetts 02472, USA., Urbé S; Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool L69 3BX, UK., Clague MJ; Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool L69 3BX, UK., Kessler BM; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK., Komander D; Medical Research Council Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK.

Publikováno v: Nature [Nature] 2017 Oct 26; Vol. 550 (7677), pp. 481-486. Date of Electronic Publication: 2017 Oct 18.

Structure-based optimization of protein tyrosine phosphatase 1B inhibitors: from the active site to the second phosphotyrosine binding site.

Autor: Wilson DP; Chemical and Screening Sciences, and Cardiovascular and Metabolic Diseases, Wyeth Research, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, USA., Wan ZK, Xu WX, Kirincich SJ, Follows BC, Joseph-McCarthy D, Foreman K, Moretto A, Wu J, Zhu M, Binnun E, Zhang YL, Tam M, Erbe DV, Tobin J, Xu X, Leung L, Shilling A, Tam SY, Mansour TS, Lee J

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2007 Sep 20; Vol. 50 (19), pp. 4681-98. Date of Electronic Publication: 2007 Aug 17.